Reference health
A combinatorial strategy for treating KRAS-mutant lung cancer
35/35 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 35 checked references that resolve
resolves10.1038/nature12796
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
resolves10.1038/nature08460
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
resolves10.1016/j.cell.2009.03.017
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
resolves10.1016/j.cell.2009.05.006
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
resolves10.1016/j.ccr.2014.03.011
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
resolves10.1016/j.celrep.2014.02.045
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
resolves10.1038/nbt.1720
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi
resolves10.1158/2159-8290.CD-13-0070
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
resolves10.1016/j.ccr.2014.05.019
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
resolves10.1038/nature09626
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
resolves10.1016/j.ccr.2010.11.023
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
resolves10.1158/2159-8290.CD-11-0341
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of
<i>BRAF</i>
-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
resolves10.1038/nature10868
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
resolves10.1016/j.cell.2012.02.053
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
resolves10.1016/S0092-8674(00)80252-4
A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway
resolves10.1158/1535-7163.MCT-11-0450
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
resolves10.1021/jm2006222
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
resolves10.1158/0008-5472.CAN-11-3034
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
resolves10.1158/2159-8290.CD-14-0763
FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors
resolves10.1182/blood-2013-07-518381
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
resolves10.1158/0008-5472.CAN-05-2193
The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer
resolves10.1158/1078-0432.CCR-11-2381
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
resolves10.1016/j.molcel.2011.02.008
Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay
resolves10.1158/0008-5472.CAN-09-1947
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
resolves10.1038/onc.2015.38
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2
resolves10.1038/nprot.2009.95
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
resolves10.1038/emboj.2013.204
Unlimited in vitro expansion of adult bi‐potent pancreas progenitors through the Lgr5/R‐spondin axis
The 1 reference without a DOI — listed, not checked
no DOI — not checkedTaylor, J., Schenck, I., Blankenberg, D. & Nekrutenko, A. in Current Protocols in Bioinformatics (eds Baxevanis, A. D. et al. ) Ch. 10, Unit 10.5 (Wiley, 2007)
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1038/nature18600"><img src="https://citestamp.com/citestamped/10.1038/nature18600/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1038/nature18600)